+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis C Virus (HCV) - Epidemiology Forecast to 2030

  • ID: 5206754
  • Report
  • December 2020
  • Region: Global
  • 150 pages
  • DelveInsight
This ‘Hepatitis C Virus (HCV) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted HCV epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hepatitis C Virus (HCV) Understanding

Hepatitis C is a viral infection that causes liver inflammation and damage, sometimes leading to serious liver disorder. HCV spreads through contaminated blood or body fluids. High-risk settings include IDU and the transfusion of unscreened blood and blood products, unsafe injection practices, unsafe health care. Other possible but less well-characterized risk exposures include tattoos and piercings, needle sticks, and unsafe/traumatic sexual practices.

HCV can range from a mild illness lasting a few weeks to a serious, long-term illness. HCV can be acute or chronic. Acute HCV occurs within the first 6 months after the patient is exposed to HCV. Around 55-85% of infected persons develop chronic HCV infection. Chronic HCV can be a lifelong infection if left untreated. Chronic HCV can cause serious health problems, including liver damage, cirrhosis (scarring of the liver), liver cancer, and even death. Most patients with newly acquired HCV do not exhibit symptoms of infection within the first 6 months. For people who develop symptoms, they usually happen 2-12 weeks after exposure to the HCV and can include yellow skin or eyes, not wanting to eat, upset stomach, throwing up, stomach pain, fever, dark urine, light-colored stool, joint pain, and feeling tired. Most chronic hepatitis C people do not have any symptoms or have only general symptoms like chronic fatigue and depression.

HCV is distinguished into different categories called genotypes based on similar genes. HCV genotypes are 1 (1a and 1b), 2, 3, 4, 5, and 6. In the United States, genotypes 1, 2, and 3 are the most common. Genotype 3 is the second most common HCV subtype in the world and most hard to treat because of the rapid progression of liver disease, increased rates of steatosis (non-alcoholic fatty liver disease), and a higher risk for cancer (hepatocellular carcinoma).

Hepatitis C Virus (HCV) Diagnosis

HCV is diagnosed based on the patient's medical history, a physical exam, and blood tests. If a viral infection is confirmed, doctors may suggest additional tests to check the condition of the liver.

Initial testing for the diagnosis of hepatitis C infection uses serologic assays that detect human antibodies generated as a response to HCV infection. Blood tests for HCV include screening tests for antibodies to the HCV virus, HCV RNA test, Genotype test, etc.

In Chronic HCV, doctors may recommend additional tests to find out how much liver damage the patient has, or to rule out other causes of liver disease. These tests may include blood tests, Imaging Tests (Transient elastography, Ultrasound, MRI, and CT Scan), and Liver function Tests (ALT, AST, ALP, and total bilirubin). If the liver is damaged due to inflammation, enzymes pass out of the liver into the bloodstream, making ALT and AST levels higher than normal. The doctor may also recommend a liver biopsy if blood tests or imaging studies suggest the patient might have a liver problem. A biopsy can determine the extent of scarring, or fibrosis, in a liver affected by viral hepatitis.

Epidemiology Perspective

The HCV epidemiology division provides insights about historical and current HCV patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the total prevalent case of HCV was 8,257,162 cases in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted HCV epidemiology [segmented as Total Prevalent Cases of HCV, Total Diagnosed Cases of HCV, Gender-specific Cases of HCV, Age-specific Diagnosed Cases of HCV, Genotype-specific Diagnosed Cases of HCV, Diagnosed Cases of HCV by Impact on Liver, and Treated cases of HCV] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- HCV Epidemiology

Estimates show that the highest cases of HCV in the 7MM were in the United States, followed by Japan, Italy, Spain, France, Germany, and the United Kingdom in 2017.
  • In the United States, the total number of prevalent cases of HCV was 3,251,471 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.
  • In the year 2017, the total prevalent cases of HCV were 3,108,919 cases in EU-5 which are expected to grow during the study period, i.e., 2017-2030.
  • In Japan, the total number of prevalent cases of HCV was 1,896,771 cases in the year 2017 which are expected to grow during the study period, i.e., 2017-2030.
Scope of the Report
  • The HCV report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The HCV Report and Model provide an overview of the risk factors and global trends of HCV in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of HCV in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of HCV.
  • The report provides the segmentation of the HCV epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the HCV epidemiology by total diagnosed cases in the 7MM.
  • The report provides the segmentation of the HCV epidemiology by gender-specific cases in the 7MM.
  • The report provides the segmentation of the HCV epidemiology by age-specific diagnosed cases in the 7MM.
  • The report provides the segmentation of the HCV epidemiology by genotype-specific diagnosed cases in the 7MM.
  • The report provides the segmentation of the HCV epidemiology by diagnosed cases by the impact on the liver in the 7MM.
  • The report provides the segmentation of the HCV epidemiology by treated cases in the 7MM.
Report Highlights
  • 11-Year Forecast of HCV epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of HCV
  • Total Diagnosed Cases of HCV
  • Gender-specific Cases of HCV
  • Age-specific Diagnosed Cases of HCV
  • Genotype-specific Diagnosed Cases of HCV
  • Diagnosed Cases of HCV by Impact on Liver
  • Treated Cases of HCV
KOL Views

The publisher interviews KOL's and SME's opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM concerning the patient population of HCV?
  • What are the key findings of the HCV epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of HCV across the 7MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of HCV?
Reasons to Buy

The HCV Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global HCV market
  • Quantify patient populations in the global HCV market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the gender that presents the best opportunities for HCV therapeutics in each of the markets covered
  • Understand the magnitude of HCV population by its severity
  • The HCV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The HCV Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030
  • In the year 2017, the total prevalent case of HCV was 8,257,162 cases in the 7MM, and the US, in 2017, accounted for 3,251,471 cases (the highest number), which will probably rise during the study period, i.e., 2017-2030.
  • In the 7MM, the total gender-specific cases of HCV were 2,524,663 for males and 1,836,170 for females in the year 2017.
  • In the 7MM, the age-specific diagnosed cases of HCV were 21,821, 157,489, 139,938, 310,234, 1,531,723, and 2,199,629 cases for the age group less than 18 years, 18-25 years, 26-35 years, 36-45 years, 46-55 years, and ≥56 years, in 2017.
  • In the 7MM, the genotype-specific diagnosed cases of HCV were 2,896,948, 688,014, 419,236, 226,662, 5,986, 18,881, and 103,661 cases for the Genotype 1, Genotype 2, Genotype 3, Genotype 4, Genotype 5, Genotype 6, and Mixed or other, in 2017.
  • In 2017, there were nearly 872,167 decompensated liver cases, and 3,488,667 Compensated Liver cases in the 7MM.
Note: Product cover images may vary from those shown
1. Key Insights

2. Executive Summary of the Hepatitis C Virus (HCV)

3. SWOT Analysis of Hepatitis C Virus (HCV)

4. Epidemiology Methodology

5. Hepatitis C Virus (HCV): Disease Background and Overview
5.1. Introduction
5.1.1. Signs and Symptoms of HCV
5.1.2. Risk Factors and Causes of HCV
5.1.3. Pathophysiology of HCV
5.1.4. Complications of HCV Infection

6. Diagnosis of Hepatitis C Infection
6.1. Screening for HCV infection
6.2. HCV RNA Testing
6.3. HCV Genotype Testing
6.4. HCV Resistance Testing (RAV testing)
6.5. Tests to Diagnose HCV
6.5.1. Medical History and Physical exam
6.5.2. Imaging Tests
6.5.3. Liver Biopsy
6.6. The differential diagnosis for Hepatitis C

7. Prevention of HCV

8. Diagnostic Guidelines of HCV
8.1. Centers for Disease Control and Prevention (CDC) Recommendations for Hepatitis C screening among Adults in the United States
8.2. US Preventive Services Task Force (USPSTF) Recommendations for the screening of HCV infection in Adolescents and Adults
8.3. American Association for the Study of Liver Diseases (AASLD) Diagnostic Guidelines
8.4. World Health Organization (WHO) Diagnostic Guidelines
8.5. EASL recommendations on treatment of hepatitis C 2020

9. Epidemiology and Patient Population
9.1. Epidemiology Key Findings
9.2. Assumptions and Rationale: 7MM

10. Epidemiology Scenario: 7MM
10.1. Total Prevalent Cases of HCV in the 7MM
10.2. Total Diagnosed cases of HCV in the 7MM
10.3. Gender-specific cases of HCV in the 7MM
10.4. Age-specific Diagnosed Cases of HCV in the 7MM
10.5. Genotype-specific Diagnosed Cases of HCV in the 7MM
10.6. Diagnosed Cases of HCV by Impact on Liver in the 7MM
10.7. Treated cases of HCV in the 7MM

11. The United States Epidemiology
11.1. Total Prevalent Cases of HCV in the United States
11.2. Total Diagnosed cases of HCV in the United States
11.3. Gender-specific cases of HCV in the United States
11.4. Age-specific Diagnosed Cases of HCV in the United States
11.5. Genotype-specific Diagnosed Cases of HCV in the United States
11.6. Diagnosed Cases of HCV by Impact on Liver in the United States
11.7. Treated cases of HCV in the United States

12. EU-5 Epidemiology
12.1. Germany
12.1.1. Total Prevalent Cases of HCV in Germany
12.1.2. Total Diagnosed cases of HCV in Germany
12.1.3. Gender-specific cases of HCV in Germany
12.1.4. Age-specific Diagnosed Cases of HCV in Germany
12.1.5. Genotype-specific Diagnosed Cases of HCV in Germany
12.1.6. Diagnosed Cases of HCV by Impact on Liver in Germany
12.1.7. Treated cases of HCV in Germany
12.2. France
12.2.1. Total Prevalent Cases of HCV in France
12.2.2. Total Diagnosed cases of HCV in France
12.2.3. Gender-specific cases of HCV in France
12.2.4. Age-specific Diagnosed Cases of HCV in France
12.2.5. Genotype-specific Diagnosed Cases of HCV in France
12.2.6. Diagnosed Cases of HCV by Impact on Liver in France
12.2.7. Treated cases of HCV in France
12.3. Italy
12.3.1. Total Prevalent Cases of HCV in Italy
12.3.2. Total Diagnosed cases of HCV in Italy
12.3.3. Gender-specific cases of HCV in Italy
12.3.4. Age-specific Diagnosed Cases of HCV in Italy
12.3.5. Genotype-specific Diagnosed Cases of HCV in Italy
12.3.6. Diagnosed Cases of HCV by Impact on Liver in Italy
12.3.7. Treated cases of HCV in Italy
12.4. Spain
12.4.1. Total Prevalent Cases of HCV in Spain
12.4.2. Total Diagnosed cases of HCV in Spain
12.4.3. Gender-specific cases of HCV in Spain
12.4.4. Age-specific Diagnosed Cases of HCV in Spain
12.4.5. Genotype-specific Diagnosed Cases of HCV in Spain
12.4.6. Diagnosed Cases of HCV by Impact on Liver in Spain
12.4.7. Treated cases of HCV in Spain
12.5. The United Kingdom
12.5.1. Total Prevalent Cases of HCV in the United Kingdom
12.5.2. Total Diagnosed cases of HCV in the United Kingdom
12.5.3. Gender-specific cases of HCV in the United Kingdom
12.5.4. Age-specific Diagnosed Cases of HCV in the United Kingdom
12.5.5. Genotype-specific Diagnosed Cases of HCV in the United Kingdom
12.5.6. Diagnosed Cases of HCV by Impact on Liver in the United Kingdom
12.5.7. Treated cases of HCV in the United Kingdom

13. Japan Epidemiology
13.1. Total Prevalent Cases of HCV in Japan
13.2. Total Diagnosed cases of HCV in Japan
13.3. Gender-specific cases of HCV in Japan
13.4. Age-specific Diagnosed Cases of HCV in Japan
13.5. Genotype-specific Diagnosed Cases of HCV in Japan
13.6. Diagnosed Cases of HCV by Impact on Liver in Japan
13.7. Treated cases of HCV in Japan

14. Appendix
14.1. Bibliography
14.2. Report Methodology

15. Publisher Capabilities

16. Disclaimer

17. About the Publisher

List of Tables
Table 1: Summary of the Hepatitis C Virus (HCV) Epidemiology (2017-2030)
Table 2: HCV Antibody and HCV RNA Test Result Interpretations
Table 3: Summary of Recommendations
Table 4: Summary of Recommendations
Table 5: Summary of Recommendations
Table 6: Summary of Recommendations
Table 7: Summary of Recommendations
Table 8: Summary of Recommendations
Table 9: Summary of Recommendations
Table 10: Summary of Recommendations
Table 11: Summary of Recommendations
Table 12: Summary of Recommendations
Table 13: Summary of Recommendations
Table 14: Total Prevalent Cases of HCV in the 7MM (2017-2030)
Table 15: Total Diagnosed cases of HCV in the 7MM (2017-2030)
Table 16: Gender-specific cases of HCV in the 7MM (2017-2030)
Table 17: Age-specific Diagnosed Cases of HCV in the 7MM (2017-2030)
Table 18: Genotype-specific Diagnosed Cases of HCV in the 7MM (2017-2030)
Table 19: Diagnosed Cases of HCV by Impact on Liver in the 7MM (2017-2030)
Table 20: Total Treated cases of HCV in the 7MM (2017-2030)
Table 21: Total Prevalent Cases of HCV in the United States (2017-2030)
Table 22: Total Diagnosed cases of HCV in the United States (2017-2030)
Table 23: Gender-specific cases of HCV in the United States (2017-2030)
Table 24: Age-specific Diagnosed Cases of HCV in the United States (2017-2030)
Table 25: Genotype-specific Diagnosed Cases of HCV in the United States (2017-2030)
Table 26: Diagnosed Cases of HCV by Impact on Liver in the United States (2017-2030)
Table 27:Total Treated cases of HCV in the United States (2017-2030)
Table 28: Total Prevalent Cases of HCV in Germany (2017-2030)
Table 29: Total Diagnosed cases of HCV in Germany (2017-2030)
Table 30: Gender-specific cases of HCV in Germany (2017-2030)
Table 31: Age-specific Diagnosed Cases of HCV in Germany (2017-2030)
Table 32: Genotype-specific Diagnosed Cases of HCV in Germany (2017-2030)
Table 33: Diagnosed Cases of HCV by Impact on Liver in Germany (2017-2030)
Table 34: Total Treated cases of HCV in Germany (2017-2030)
Table 35: Total Prevalent Cases of HCV in France (2017-2030)
Table 36: Total Diagnosed cases of HCV in France (2017-2030)
Table 37: Gender-specific cases of HCV in France (2017-2030)
Table 38: Age-specific Diagnosed Cases of HCV in France (2017-2030)
Table 39: Genotype-specific Diagnosed Cases of HCV in France (2017-2030)
Table 40: Diagnosed Cases of HCV by Impact on Liver in France (2017-2030)
Table 41: Total Treated cases of HCV in France (2017-2030)
Table 42: Total Prevalent Cases of HCV in Italy (2017-2030)
Table 43: Total Diagnosed cases of HCV in Italy (2017-2030)
Table 44: Gender-specific cases of HCV in Italy (2017-2030)
Table 45: Age-specific Diagnosed Cases of HCV in Italy (2017-2030)
Table 46: Genotype-specific Diagnosed Cases of HCV in Italy (2017-2030)
Table 47: Diagnosed Cases of HCV by Impact on Liver in Italy (2017-2030)
Table 48: Total Treated cases of HCV in Italy (2017-2030)
Table 49:Total Prevalent Cases of HCV in Spain (2017-2030)
Table 50: Total Diagnosed cases of HCV in Spain (2017-2030)
Table 51: Gender-specific cases of HCV in Spain (2017-2030)
Table 52: Age-specific Diagnosed Cases of HCV in Spain (2017-2030)
Table 53: Genotype-specific Diagnosed Cases of HCV in Spain (2017-2030)
Table 54: Diagnosed Cases of HCV by Impact on Liver in Spain (2017-2030)
Table 55: Total Treated cases of HCV in Spain (2017-2030)
Table 56:Total Prevalent Cases of HCV in the United Kingdom (2017-2030)
Table 57: Total Diagnosed cases of HCV in the United Kingdom (2017-2030)
Table 58: Gender-specific cases of HCV in the United Kingdom (2017-2030)
Table 59: Age-specific Diagnosed Cases of HCV in the United Kingdom (2017-2030)
Table 60: Genotype-specific Diagnosed Cases of HCV in the United Kingdom (2017-2030)
Table 61: Diagnosed Cases of HCV by Impact on Liver in the United Kingdom (2017-2030)
Table 62: Total Treated cases of HCV in the United Kingdom (2017-2030)
Table 63: Total Prevalent Cases of HCV in Japan (2017-2030)
Table 64: Total Diagnosed cases of HCV in Japan (2017-2030)
Table 65: Gender-specific cases of HCV in Japan (2017-2030)
Table 66: Age-specific Diagnosed Cases of HCV in Japan (2017-2030)
Table 67: Genotype-specific Diagnosed Cases of HCV in Japan (2017-2030)
Table 68: Diagnosed Cases of HCV by Impact on Liver in Japan (2017-2030)
Table 69: Total Treated cases of HCV in Japan (2017-2030)

List of Figures
Figure 1: Hepatitis C Virus (HCV) SWOT Analysis
Figure 2: Epidemiology Methodology
Figure 3: Progression of HCV Infection
Figure 4: Signs and symptoms of HCV
Figure 5: Causes of HCV
Figure 6: HCV Viral Cycle
Figure 7: Complications of HCV Infection
Figure 8: Diagnostic Algorithm of HCV
Figure 9: OraQuick HCV Rapid Antibody Test
Figure 10: Ultrasound
Figure 11: Total Prevalent Cases of HCV in the 7MM (2017-2030)
Figure 12: Total Diagnosed cases of HCV in the 7MM (2017-2030)
Figure 13: Gender-specific cases of HCV in the 7MM (2017-2030)
Figure 14: Age-specific Diagnosed Cases of HCV in the 7MM (2017-2030)
Figure 15: Genotype-specific Diagnosed Cases of HCV in the 7MM (2017-2030)
Figure 16: Diagnosed Cases of HCV by Impact on Liver in the 7MM (2017-2030)
Figure 17: Treated cases of HCV in the 7MM (2017-2030)
Figure 18: Total Prevalent Cases of HCV in the United States (2017-2030)
Figure 19: Total Diagnosed cases of HCV in the United States (2017-2030)
Figure 20: Gender-specific cases of HCV in the United States (2017-2030)
Figure 21: Age-specific Diagnosed Cases of HCV in the United States (2017-2030)
Figure 22: Genotype-specific Diagnosed Cases of HCV in the United States (2017-2030)
Figure 23: Diagnosed Cases of HCV by Impact on Liver in the United States (2017-2030)
Figure 24: Treated cases of HCV in the United States (2017-2030)
Figure 25: Total Prevalent Cases of HCV in Germany (2017-2030)
Figure 26: Total Diagnosed cases of HCV in Germany (2017-2030)
Figure 27: Gender-specific cases of HCV in Germany (2017-2030)
Figure 28:Age-specific Diagnosed Cases of HCV in Germany (2017-2030)
Figure 29: Genotype-specific Diagnosed Cases of HCV in Germany (2017-2030)
Figure 30: Diagnosed Cases of HCV by Impact on Liver in Germany (2017-2030)
Figure 31: Treated cases of HCV in Germany (2017-2030)
Figure 32: Total Prevalent Cases of HCV in France (2017-2030)
Figure 33: Total Diagnosed cases of HCV in France (2017-2030)
Figure 34: Gender-specific cases of HCV in France (2017-2030)
Figure 35:Age-specific Diagnosed Cases of HCV in France (2017-2030)
Figure 36: Genotype-specific Diagnosed Cases of HCV in France (2017-2030)
Figure 37: Diagnosed Cases of HCV by Impact on Liver in France (2017-2030)
Figure 38: Treated cases of HCV in France (2017-2030)
Figure 39: Total Prevalent Cases of HCV in Italy (2017-2030)
Figure 40: Total Diagnosed cases of HCV in Italy (2017-2030)
Figure 41: Gender-specific cases of HCV in Italy (2017-2030)
Figure 42: Age-specific Diagnosed Cases of HCV in Italy (2017-2030)
Figure 43: Genotype-specific Diagnosed Cases of HCV in Italy (2017-2030)
Figure 44: Diagnosed Cases of HCV by Impact on Liver in Italy (2017-2030)
Figure 45: Treated cases of HCV in Italy (2017-2030)
Figure 46: Total Prevalent Cases of HCV in Spain (2017-2030)
Figure 47: Total Diagnosed cases of HCV in Spain (2017-2030)
Figure 48: Gender-specific cases of HCV in Spain (2017-2030)
Figure 49: Age-specific Diagnosed Cases of HCV in Spain (2017-2030)
Figure 50: Genotype-specific Diagnosed Cases of HCV in Spain (2017-2030)
Figure 51: Diagnosed Cases of HCV by Impact on Liver in Spain (2017-2030)
Figure 52: Treated cases of HCV in Spain (2017-2030)
Figure 53: Total Prevalent Cases of HCV in the United Kingdom (2017-2030)
Figure 54: Total Diagnosed cases of HCV in the United Kingdom (2017-2030)
Figure 55: Gender-specific cases of HCV in the United Kingdom (2017-2030)
Figure 56: Age-specific Diagnosed Cases of HCV in the United Kingdom (2017-2030)
Figure 57: Genotype-specific Diagnosed Cases of HCV in the United Kingdom (2017-2030)
Figure 58: Diagnosed Cases of HCV by Impact on Liver in the United Kingdom (2017-2030)
Figure 59: Treated cases of HCV in the United Kingdom (2017-2030)
Figure 60: Total Prevalent Cases of HCV in Japan (2017-2030)
Figure 61: Total Diagnosed cases of HCV in Japan (2017-2030)
Figure 62: Gender-specific cases of HCV in Japan (2017-2030)
Figure 63: Age-specific Diagnosed Cases of HCV in Japan (2017-2030)
Figure 64: Genotype-specific Diagnosed Cases of HCV in Japan (2017-2030)
Figure 65: Diagnosed Cases of HCV by Impact on Liver in Japan (2017-2030)
Figure 66: Treated cases of HCV in Japan (2017-2030)
Note: Product cover images may vary from those shown
Adroll
adroll